Search the Newsreel

Needham Maintains Veradermics(MANE.US) With Buy Rating, Maintains Target Price $164

Needham has reiterated its Buy rating for Veradermics (MANE.US) and maintained its price target of $164. This indicates continued confidence in the company's stock performance by the investment firm.

Veradermics, Inc SEC Filing (Aug 12, 2026)

This article details an SEC Form 144 filing by Veradermics, Inc. (MANE) on August 12, 2026. The filing indicates a proposed sale of 104,587 shares of common stock with an aggregate market value of $11,394,753.65 through Merrill Lynch. The shares were acquired via a …

Veradermics: Q2 Earnings Snapshot

Veradermics Inc. (MANE) reported a significant loss of $23.5 million, or 58 cents per share, in its second quarter. The New Haven, Connecticut-based company's financial results were disclosed on Tuesday, August 11, 2026. This data was compiled by Automated Insights using information from Zacks …

J&E Davy Reports Acquisition of 15,036 Permanent TSB Shares at €2.94 Under Irish Takeover Panel Regulations

Société Générale Reports 2.18% Stake in Permanent TSB Group Holdings plc (-PTSB) via Form 8.3 Filing

Veradermics Q2 Results: EPS of $(0.58) Beats Estimate

Veradermics (NYSE: MANE) posts larger loss as cash surges above $800M

Veradermics (NYSE: MANE) reported a significantly larger net loss of $50.7 million for the first half of 2026, compared to $28.0 million in the prior year, primarily due to increased operating expenses in research and development and general and administrative costs. Despite the losses, …

Veradermics reports Q2 2026 net loss $23.5M; cash $819.9M funds operations into 2030

Veradermics reported a net loss of $23.5 million for Q2 2026, an increase from $15.6 million in Q2 2025, driven by higher R&D and G&A expenses. Despite the loss, the company holds a strong cash position of $819.9 million, expected to fund operations into …

Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Veradermics announced positive second-quarter 2026 financial results and significant clinical progress for its lead drug candidate, VDPHL01, an extended-release oral minoxidil for pattern hair loss. The company reported positive Phase 2 results for female pattern hair loss, completed enrollment for a pivotal Phase 2/3 …

Earnings Flash (MANE) Veradermics Posts Q2 Net Loss $23.5M, vs. FactSet Est of $26.8M Loss

Goldman Sachs International Reports Trades in Permanent TSB Group Holdings Plc (-PTSB) Shares and CFDs on August 10, 2026

Veradermics (MANE) Q1 2026 Earnings: Wider-than-Expected Loss Triggers Stock Decline - Strong Earnings Momentum

FMR LLC discloses 7.6% Veradermics Inc. (MANE) ownership in Schedule 13G

FMR LLC and Abigail P. Johnson have disclosed a 7.6% passive ownership stake in Veradermics Inc. (MANE) common stock through a Schedule 13G filing. The filing indicates beneficial ownership of 3,193,181 shares as of June 30, 2026, with FMR LLC holding sole voting and …

Goldman Sachs Bank Europe SE Reports Exempt Principal Trader Activity in Permanent TSB Group Holdings Plc (PTSB) Shares

Goldman Sachs International Reports Significant Transactions in Permanent TSB Group Holdings plc (PTSB) Shares and Derivatives

Price to sales forward of Veradermics, Incorporated – NYSE:MANE

This article provides a brief financial overview for Veradermics, Incorporated (NYSE: MANE), specifically focusing on its price-to-sales forward metric. It appears to be a snapshot from a financial data platform, indicating that the market is closed and no trades have occurred for the company. …

Veradermics (MANE) Positioned to Disrupt Hair Loss Market

Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 …

REG - Syquant Capital Permanent TSB Group - Form 8.3: PTSB ID

J&E Davy Reports Exempt Principal Trader Transactions in Permanent TSB Group Holdings PLC (PTSB) Shares on August 3, 2026

Veradermics Falls 4.4% as Lock-Up Expiry Appears to Weigh on Shares

Veradermics (MANE) shares dropped 4.4% due to the expiration of post-IPO lock-up restrictions, allowing 20,000,170 shares to become eligible for resale. This decline is attributed to share-supply pressure rather than negative clinical news, as the company recently reported positive Phase 2 data and is …

Permanent TSB (ISE:PTSB) Stock Faces Profit Slowdown As Valuation Questions Build

REG - BAWAG Group AG Permanent TSB Group - PTSB acquisition: Shareholders approve transaction

PTA-News: BAWAG Group AG: PTSB acquisition reaches next milestone

PTSB underlying profit jumps 34% ahead of vote on Bawag takeover

PTSB posts profit jump ahead of takeover vote

14,570,076 Common Stock of Veradermics, Incorporated are subject to a Lock-Up Agreement Ending on 29-JUL-2026.

Approximately 14.57 million common shares of Veradermics, Incorporated are under a lock-up agreement that concludes on July 29, 2026. This 91-day lock-up period, which began on April 29, 2026, prevents the company's directors, executive officers, and certain affiliates from selling or transferring these shares …

Veradermics, Incorporated's Lock-Up Period Set To End on August 3rd (NYSE:MANE)

Veradermics, Inc. (NYSE: MANE) will see its IPO lock-up period expire on August 3rd, potentially allowing major shareholders and insiders to sell their shares. The company, which focuses on dermatological treatments, including pattern hair loss, issued 15.1 million shares at $17 each in February. …

Veradermics, Incorporated Revenue Breakdown – NYSE:MANE

This article provides details on Veradermics, Incorporated (NYSE: MANE) financials, including an overview of statements, statistics, dividends, earnings, and segments. It highlights top segments and regional performance by source and country, indicating that the data is provided by ICE Data Services and FactSet. The …

PERMANENT TSB GROUP HOLDINGS PLC Revenue Breakdown – EURONEXT:PTSB

REG - BAWAG Group AG Permanent TSB Group - BAWAG Q2 2026 Results & Update

Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months

Veradermics' investigational oral drug VDPHL01 for female pattern hair loss showed positive results in a Phase 2 trial, demonstrating consistent hair growth and early activity within two months. The treatment was well-tolerated, with participants experiencing clinically meaningful improvements in hair count and coverage. The …

Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy

Veradermics, Incorporated announced the presentation of data from a subgroup analysis of its Phase 2/3 study '302' for VDPHL01 in male patients with pattern hair loss. The data were shared at the 2026 American Academy of Dermatology Innovation Academy, detailing the efficacy and safety …

Weekly Buzz: NVS, MRK Win FDA Nod; LLY Snaps Up ATAI; MANE Shines On Hair Loss Data

(RTTNews) - This week, the healthcare sector saw multiple U.S FDA and European Commission approvals, strategic licensing and M&A activity, as well as pivotal clinical trial readouts and regulatory setbacks. Positive data readouts spanned multiple therapeutic areas, including pulmonary arterial hypertension, weight loss, pattern …